HLB rewrites biotech playbook with overseas pipeline, US subsidiary

South Korean biotech HLB has created a hybrid global business model by licensing Phase 1/2 validated drug candidates from overseas biotechs and using its US subsidiary Elevar Therapeutics to secure FDA approval and directly commercialise treatments, exemplified by the recent approval of Lyfgenia for cholangiocarcinoma. This strategy overcomes traditional biotech challenges by avoiding early-stage licensing drawbacks and eliminating the decade-long in-house drug development risk, enabling faster market access and full margin capture in the US.

This Wire brief sits within Fusion42's coverage of Biotech.